View Past PerformanceNovanta バランスシートの健全性財務の健全性 基準チェック /66Novantaの総株主資本は$1.3B 、総負債は$241.4Mで、負債比率は18.4%となります。総資産と総負債はそれぞれ$1.8Bと$488.0Mです。 Novantaの EBIT は$116.3Mで、利息カバレッジ比率6.6です。現金および短期投資は$388.8Mです。主要情報18.41%負債資本比率US$241.42m負債インタレスト・カバレッジ・レシオ6.6x現金US$388.80mエクイティUS$1.31b負債合計US$488.03m総資産US$1.80b財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 11Novanta Inc. (NasdaqGS:NOVT) entered into a definitive agreement to acquire Riverpoint Medical, LLC from Arlington Capital Partners V, L.P., a fund managed by Arlington Management Employees, LLC for $1.5 billion.Novanta Inc. (NasdaqGS:NOVT) entered into a definitive agreement to acquire Riverpoint Medical, LLC from Arlington Capital Partners V, L.P., a fund managed by Arlington Management Employees, LLC for $1.5 billion on June 8, 2026. A cash consideration of $1.2 billion will be paid by Novanta Inc. Novanta Inc. will pay a milestone payment of $250 million in the first quarter of 2027. Upon completion of the transaction, Riverpoint Medical will be reported under Novanta’s Medical Solutions operating segment. The transaction will be financed through a combination of cash on hand and Novanta’s existing credit facility, and the recently completed $300 million equity raise. The transaction is subject to customary regulatory approvals and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction is expected to close in the third quarter of 2026. The transaction is expected to be immediately accretive in 2026 to Novanta’s Adjusted Diluted Earnings Per Share, and in 2027 accretive to revenue growth rate, Adjusted Gross and EBITDA Margins, Adjusted Diluted Earnings Per Share, and Operating Cash Flows. Robert W. Baird & Co. Incorporated acted as financial advisor for Novanta Inc. Jefferies LLC acted as financial advisor for Riverpoint Medical, LLC. J.P. Morgan Securities LLC acted as financial advisor for Novanta Inc. King & Spalding LLP acted as legal advisor for Novanta Inc. Matthew J. Byron, Melissa Rones, Emily Karlberg, Renata Ferrari, Pamela Glazier, Samer Musallam, Lisa Kaltenbrunner, Emerson Siegle, Deidre Johnson, Ryan Murphey, Rebecca Liu, Heather Sprague, Alison McLaughlin, and Kurt Fowler of Ropes & Gray LLP acted as legal advisor for Novanta Inc. Joshua Klatzkin, Matthew M. Mauney, and Michael Amalfe of Goodwin Procter LLP acted as legal advisor for Riverpoint Medical, LLC.お知らせ • Jun 10Novanta Inc. announced that it expects to receive $299.99998 million in fundingNovanta Inc. entered into a Securities Purchase Agreement and announced a private placement of 2,142,857 Common Shares of the company at an issue price of $140 for gross proceeds up to $300.0 million on June 8, 2026. The transaction involves participation from institutional and other accredited investors. The private placement is expected to close on or about June 11, 2026, subject to satisfaction of customary closing conditions.お知らせ • May 12Novanta Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2026Novanta Inc. provided earnings guidance for the second quarter and full year of 2026. For the quarter, the company expects GAAP revenue to be in the range of $259 million to $264 million. For the year, the company expects GAAP revenue to be in the range of $1,040 million to $1,055 million.お知らせ • Apr 14Novanta Inc. to Report Q1, 2026 Results on May 11, 2026Novanta Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 11, 2026お知らせ • Feb 24Novanta Inc. Provides Revenue Guidance for the First Quarter and for the Full Year 2026Novanta Inc. provided revenue guidance for the first quarter and For the full year 2026. For the first quarter of 2026, the Company expects GAAP revenue to be in the range of $250 million to $255 million. For the full year, the Company expects GAAP revenue to be in the range of $1,030 million to $1,050 million.お知らせ • Feb 10Novanta Inc., Annual General Meeting, May 28, 2026Novanta Inc., Annual General Meeting, May 28, 2026.お知らせ • Jan 22Novanta Inc. to Report Q4, 2025 Results on Feb 24, 2026Novanta Inc. announced that they will report Q4, 2025 results Pre-Market on Feb 24, 2026お知らせ • Nov 07Novanta Inc. has completed a Composite Units Offering in the amount of $550 million.Novanta Inc. has completed a Composite Units Offering in the amount of $550 million. Security Name: Units Security Type: Debt/Equity Composite Units Securities Offered: 11,000,000 Price\Range: $50 Discount Per Security: $1.375財務状況分析短期負債: NOVT.Uの 短期資産 ( $786.8M ) が 短期負債 ( $220.8M ) を超えています。長期負債: NOVT.Uの短期資産 ( $786.8M ) が 長期負債 ( $267.2M ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: NOVT.U総負債よりも多くの現金を保有しています。負債の削減: NOVT.Uの負債対資本比率は、過去 5 年間で40.2%から18.4%に減少しました。債務返済能力: NOVT.Uの負債は 営業キャッシュフロー によって 十分にカバー されています ( 34.8% )。インタレストカバレッジ: NOVT.Uの負債に対する 利息支払い は EBIT ( 6.6 x coverage) によって 十分にカバーされています。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YTech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 20:23終値2026/06/16 00:00収益2026/04/03年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Novanta Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Robert MasonBairdQuinn FredricksonBairdAndrew BuscagliaBerenberg5 その他のアナリストを表示
お知らせ • Jun 11Novanta Inc. (NasdaqGS:NOVT) entered into a definitive agreement to acquire Riverpoint Medical, LLC from Arlington Capital Partners V, L.P., a fund managed by Arlington Management Employees, LLC for $1.5 billion.Novanta Inc. (NasdaqGS:NOVT) entered into a definitive agreement to acquire Riverpoint Medical, LLC from Arlington Capital Partners V, L.P., a fund managed by Arlington Management Employees, LLC for $1.5 billion on June 8, 2026. A cash consideration of $1.2 billion will be paid by Novanta Inc. Novanta Inc. will pay a milestone payment of $250 million in the first quarter of 2027. Upon completion of the transaction, Riverpoint Medical will be reported under Novanta’s Medical Solutions operating segment. The transaction will be financed through a combination of cash on hand and Novanta’s existing credit facility, and the recently completed $300 million equity raise. The transaction is subject to customary regulatory approvals and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction is expected to close in the third quarter of 2026. The transaction is expected to be immediately accretive in 2026 to Novanta’s Adjusted Diluted Earnings Per Share, and in 2027 accretive to revenue growth rate, Adjusted Gross and EBITDA Margins, Adjusted Diluted Earnings Per Share, and Operating Cash Flows. Robert W. Baird & Co. Incorporated acted as financial advisor for Novanta Inc. Jefferies LLC acted as financial advisor for Riverpoint Medical, LLC. J.P. Morgan Securities LLC acted as financial advisor for Novanta Inc. King & Spalding LLP acted as legal advisor for Novanta Inc. Matthew J. Byron, Melissa Rones, Emily Karlberg, Renata Ferrari, Pamela Glazier, Samer Musallam, Lisa Kaltenbrunner, Emerson Siegle, Deidre Johnson, Ryan Murphey, Rebecca Liu, Heather Sprague, Alison McLaughlin, and Kurt Fowler of Ropes & Gray LLP acted as legal advisor for Novanta Inc. Joshua Klatzkin, Matthew M. Mauney, and Michael Amalfe of Goodwin Procter LLP acted as legal advisor for Riverpoint Medical, LLC.
お知らせ • Jun 10Novanta Inc. announced that it expects to receive $299.99998 million in fundingNovanta Inc. entered into a Securities Purchase Agreement and announced a private placement of 2,142,857 Common Shares of the company at an issue price of $140 for gross proceeds up to $300.0 million on June 8, 2026. The transaction involves participation from institutional and other accredited investors. The private placement is expected to close on or about June 11, 2026, subject to satisfaction of customary closing conditions.
お知らせ • May 12Novanta Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2026Novanta Inc. provided earnings guidance for the second quarter and full year of 2026. For the quarter, the company expects GAAP revenue to be in the range of $259 million to $264 million. For the year, the company expects GAAP revenue to be in the range of $1,040 million to $1,055 million.
お知らせ • Apr 14Novanta Inc. to Report Q1, 2026 Results on May 11, 2026Novanta Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 11, 2026
お知らせ • Feb 24Novanta Inc. Provides Revenue Guidance for the First Quarter and for the Full Year 2026Novanta Inc. provided revenue guidance for the first quarter and For the full year 2026. For the first quarter of 2026, the Company expects GAAP revenue to be in the range of $250 million to $255 million. For the full year, the Company expects GAAP revenue to be in the range of $1,030 million to $1,050 million.
お知らせ • Feb 10Novanta Inc., Annual General Meeting, May 28, 2026Novanta Inc., Annual General Meeting, May 28, 2026.
お知らせ • Jan 22Novanta Inc. to Report Q4, 2025 Results on Feb 24, 2026Novanta Inc. announced that they will report Q4, 2025 results Pre-Market on Feb 24, 2026
お知らせ • Nov 07Novanta Inc. has completed a Composite Units Offering in the amount of $550 million.Novanta Inc. has completed a Composite Units Offering in the amount of $550 million. Security Name: Units Security Type: Debt/Equity Composite Units Securities Offered: 11,000,000 Price\Range: $50 Discount Per Security: $1.375